Skip to content

Comparison of the efficacy of intralesional bleomycin plus intralesional triamcinolone in the treatment of keloids.

Comparison of the efficacy of intralesional bleomycin plus intralesional triamcinolone in the treatment of keloids in the year of 1401in Loghman and Tajrish hospital

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20221209056760N1
Enrollment
30
Registered
2023-02-17
Start date
2022-12-22
Completion date
Unknown
Last updated
2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

keloid.

Interventions

Intervention group: Patients with refractory keloids referred to the dermatology clinic of Loghman Hakim and Shohada Tajrish hospitals will be treated with intra-lesional of bleomycincin 5 mg and tria

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients between the ages of 18 and 60 Refractory keloid: Relapse or not cured despite six sessions of intra-triamcyonolone acetonide injection.

Exclusion criteria

Exclusion criteria: Dissatisfaction with the study sensitivity to bleomycin pregnant or breast feeding

Design outcomes

Primary

MeasureTime frame
Evaluation of the efficacy of keloid treatment by intralesional injection of bleomycin in combination with intralesion injection of triamcinolone.(pigmentation, vascularity, pliability and thickness). Timepoint: The Beginning of the study and then every 4 weeks and up to 6 sessions (end of study). Method of measurement: The VSS (Vancouver Scar Scale) scale and examining the patient.

Secondary

MeasureTime frame
Relapse rate. Timepoint: Beginning of the study and then every 4 weeks and up to 6 sessions (end of study). Method of measurement: The VSS (Vancouver Scar Scale) scale.;Complication of treatment. Timepoint: Beginning of the study and then every 4 weeks and up to 6 sessions (end of study). Method of measurement: observation and asking for the patients.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFaeghe Mollaabasi

Shahid Beheshti University of Medical Sciences

faegheabasi@yahoo.com+98 21 2243 9770

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026